RxDoctor Payments Data

Anne Hanneken, MD

Ophthalmology · la Jolla, CANPI 1699876011

Payments from drug & device makers

$14,587in general payments, 2019–2025

Across 51 payments — averaging $286.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$9K
  • Novo Nordisk AS$4K
  • Genentech USA, Inc.$422
  • Apellis Pharmaceuticals, Inc.$348
  • Regeneron Healthcare Solutions, Inc.$253
  • Genentech, Inc.$125
  • plus $401 from 5 others

What the payments were for

  • Food & beverage$1,50914%
  • Education$410%
  • Ownership interest$3,38832%
  • Other$5,54353%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,587 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$2,914,114
Medicare patients
882
Services billed
48,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost20$9,443
SimbrinzaBrinzolamide/Brimonidine Tart18$4,267
CombiganBrimonidine Tartrate/Timolol16$3,247
Prednisolone Acetate70$1,998
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat26$828
Latanoprost72$787
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha57$740
Timolol Maleate89$604
Brimonidine Tartrate23$529
Dorzolamide Hcl12$348
MoxifloxacinMoxifloxacin Hcl12$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$81$12,69036 claims
AlconSimbrinza$85$4,26718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →